How often to take
The recommended dose is one tablet per day.
If you are currently taking a Secalip 200 mg capsule per day, you can switch to a Secalip 160 mg tablet per day. You will still receive the same amount of medication.
Patients with kidney problems
If you have kidney problems, your doctor may recommend a lower dose. Consult your doctor or pharmacist about this.
Use in children and adolescents
Secalip is not recommended for use in children and adolescents under 18 years old.
If you take more Secalip than you should
In case of overdose or accidental ingestion, consult the Toxicological Information Service
Telephone 91 562 04 20.
If you forget to take Secalip
Then take the next dose at the usual time.
Do not take a double dose to make up for the missed doses.
If you interrupt treatment with Secalip
Do not stop taking Secalip unless your doctor tells you to or unless the tablets make you feel unwell. This is because it requires long-term treatment.
If your doctor stops the medication, do not keep the remaining tablets unless your doctor tells you to. If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Stop taking Secalip and see your doctor immediately if you notice any of the following serious side effects – you may need urgent medical treatment:
Rare:may affect up to 1 in 100 people
Rare:may affect up to 1 in 1,000 people
Unknown:cannot be estimated from available data
Stop taking Secalip and see your doctor immediately if you notice any of the side effects listed above.
Other side effects include:
• Frequent:may affect up to1 in 10 patients
• Rare:may affect up to1 in 100 patients
• Rare:may affect up to1 in 1,000 patients
•Unknown:cannot be estimated from available data
Consult your doctor or pharmacist if you experience any of the side effects listed above.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:www.notificaram.es.
By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Keep this medication in the original packaging to protect it from moisture.Do not store at a temperature above 30°C.
Do not use this medication after the expiration date that appears on the packaging and on the blister pack marked CAD or EXP. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection pointof the pharmacy.If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Secalip
The active principle is fenofibrate. Each Secalip 160 mg tablet contains 160 mg of fenofibrate.
The other components are: lactose monohydrate, sodium lauryl sulfate, povidone, crospovidone, microcrystalline cellulose, anhydrous colloidal silica, and sodium stearate fumarate.
The coating filmor padry®is composed of the following components: polyvinyl alcohol, titanium dioxide (e171), talc, soy lecithin, xanthan gum.
Appearance of the product and content of the packaging
Secalip Supra 160 mg coated tablets are white tablets.
The coated tablets are presented in blister packs of10, 20, 28, 30, 50, 84, 90, 98, 100, 280, 300.
You may not have all formats commercially available.
Holder of the marketing authorization and responsible for manufacturing
LACER, S.A. - Boters, 5
08290 Cerdanyola del Vallès
Barcelona – Spain
Responsible for manufacturing
Astrea Fontaine.
Rue des Prés Potets.
21121 Fontaine-les-Dijon
France
or
Delpharm L’Aigle
Zone Industrielle No. 1
Route Crulai
61300 L’Aigle
France
This medicine is authorized in the EU member states with the following names:
Germany:Lipidil-Ter 160 mg
France:Lipanthyl 160 mg
Spain:Secalip Supra 160 mg
United Kingdom:Supralip 160 mg
Last review date of this leaflet: December 2020
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.